期刊
CANCER CELL
卷 17, 期 6, 页码 560-573出版社
CELL PRESS
DOI: 10.1016/j.ccr.2010.04.023
关键词
-
资金
- National Institutes of Health [CA109345, CA140980, GM089927, GM062848]
- Susan G. Komen Breast Cancer Foundation
- California Breast Cancer Research Program
- U.S. Army Medical Research and Material Command
- California Tobacco-Related Diseases Research Program
- Xiamen University
- 863 Program [2007aa09z404]
- National Science Foundation [30971445, 30931160431]
Nonsteroidal anti-inflammatory drugs (NSAIDs) exert their anticancer effects through cyclooxygenase-2 (COX-2)-dependent and independent mechanisms. Here, we report that Sulindac, an NSAID, induces apoptosis by binding to retinoid X receptor-alpha (RXR alpha). We identified an N-terminally truncated RXR alpha (tRXR alpha) in several cancer cell lines and primary tumors, which interacted with the p85 alpha subunit of phosphatidylinositol-3-OH kinase (PI3K). Tumor necrosis factor-alpha (TNF alpha) promoted tRXR alpha. interaction with the p85 alpha, activating PI3K/AKT signaling. When combined with TNF alpha, Sulindac inhibited TNF alpha-induced tRXR alpha/p85 alpha interaction, leading to activation of the death receptor-mediated apoptotic pathway. We designed and synthesized a Sulindac analog K-80003, which has increased affinity to RXR alpha but lacks COX inhibitory activity. K-80003 displayed enhanced efficacy in inhibiting tRXR alpha-dependent AKT activation and tRXR alpha tumor growth in animals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据